

ASX RELEASE (ASX: MDR)

MedAdvisor Amended Appendix 4C

Melbourne, Australia – 24 November 2025 – Pharmacy driven patient engagement solutions company MedAdvisor Limited (ASX: MDR) (“MedAdvisor Solutions” or “the Company”) advises that certain line items relating to the Appendix 4C for the quarter ended 30 September 2025 lodged on 22 October 2025 were inadvertently completed incorrectly.

The affected items relate to:

- Item 2.2 – *Proceeds from disposal of businesses*
- Item 4.1 – *Cash and cash equivalents at beginning of the period*
- Items 5.1 and 5.5 – *Previous quarter bank balances and Cash and cash equivalents at end of quarter*

These items were incorrectly presented due to the inclusion of \$2.248 million in proceeds from the disposal of businesses, which should have been disclosed as part of the opening cash balance, rather than as disposal proceeds. The cash balance at the end of the period remains unchanged at \$12.995 million.

The Company has today lodged an amended Appendix 4C to correct these disclosures. No other changes have been made.

The Company apologises for this oversight and reaffirms its commitment to best practice continuous disclosure.

- ENDS -

This document has been authorised for release by the Board of MedAdvisor Limited.

For more information please contact:

Company

Sean Slattery

Chief Financial Officer

sean.slattery@medadvisorsolutions.com

+61 417 559 360

Investor Relations

George Kopsiaftis

IR Department

george.kopsiaftis@irdepartment.com.au

+61 409 392 687

About MedAdvisor Solutions

MedAdvisor Solutions (ASX: MDR) is a leader of pharmacy-driven patient engagement solutions that provide personalized patient experiences to help simplify the patient medication journey. Leveraging THRiV, a cloud-based, AI-enabled platform, MedAdvisor Solutions empowers the pharmacy of the future through improved pharmacy workflow and patient engagement solutions. MedAdvisor Solutions works with over 25,000 pharmacies across the US with reach to over two-thirds of the population. For more information, please visit: medadvisorsolutions.com/investors.

Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

Name of entity

MEDADVISOR LIMITED (ASX: MDR)

ABN

17 145 327 617

Quarter ended ("current quarter")

30 Sep 2025

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (3 months) \$A'000
1. Cash flows related to operating activities		
1.1 Receipts from customers	8,096	8,096
1.2 Payments for:	-	-
(a) research and development	-	-
(b) product manufacturing and operating costs	(5,745)	(5,745)
(c) advertising and marketing	(104)	(104)
(d) leased assets	-	-
(e) staff costs	(2,244)	(2,244)
(f) administration and corporate costs	(741)	(741)
1.3 Dividends received	-	-
1.4 Interest received	10	10
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	-	-
1.8 Other (provide details if material)	-	-
1.9 Net cash from / (used in) operating activities	(728)	(728)

Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (3 months) \$A'000
4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of the period	12,552	12,552
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(729)	(729)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	24,113	24,113
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(22,864)	(22,864)
4.5	Effect of movement in exchange rates on cash held	(77)	(77)
4.6	Cash and cash equivalents at end of the period	12,995	12,995

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous Quarter \$A'000
5.1	Bank balances	12,995	12,552
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	12,995	12,552

6. Payments to related parties of the entity and their associates

- 6.1 Aggregate amount of payments to these parties included in item 1
 6.2 Aggregate amount of cash flow from loans to these parties included in item 2

Current quarter \$A'000
311
-

6.3 Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2

Payments to related parties of the entity and their associates include: 1) fees and remuneration paid to the CEO and CFO (from his date of appointment as a Director) and directors.

Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

7 Financing facilities available	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1 Loan facilities	-	-
7.2 Credit standby arrangements	-	-
7.3 Other (please specify)	-	-
7.4 Total financing facilities	-	-

7.5 **Unused financing facilities available at quarter end** -

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

Answer: not applicable

8. Estimated cash available for future operations	\$A'000
8.1 Net cash from / (used in) operating activities (Item 1.9)	(728)
8.2 Cash and cash equivalents at quarter end (Item 4.6)	12,995
8.3 Unused finance facilities available at quarter end (Item 7.5)	-
8.4 Total available funding (Item 8.2 + Item 8.3)	12,995
8.5 Estimated quarters of funding available (Item 8.4 divided by Item 8.1)	17.85

8.6 If Item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer: not applicable

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer: not applicable

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: not applicable

Appendix 4C
Quarterly report for entities subject to Listing Rule 4.7B

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement does give a true and fair view of the matters disclosed.

Authorised by: Board of Directors - MedAdvisor Limited

Date: 24/11/2025

Notes

- 1 This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
- 2 If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
- 3 Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
- 4 If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg *Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
- 5 If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's Corporate Governance Principles and Recommendations, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.